Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1991 1
1992 2
1994 1
1995 1
1997 3
1999 3
2001 1
2002 3
2003 2
2005 1
2006 4
2007 3
2008 5
2009 12
2010 11
2011 10
2012 5
2013 14
2014 12
2015 5
2016 15
2017 19
2018 19
2019 19
2020 16
2021 19
2022 26
2023 20
2024 19
2025 21
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Results by year

Filters applied: . Clear all
Page 1
Uterine fibroids.
Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Stewart EA, et al. Nat Rev Dis Primers. 2016 Jun 23;2:16043. doi: 10.1038/nrdp.2016.43. Nat Rev Dis Primers. 2016. PMID: 27335259 Review.
Evaluation and Management of Abnormal Uterine Bleeding.
Marnach ML, Laughlin-Tommaso SK. Marnach ML, et al. Mayo Clin Proc. 2019 Feb;94(2):326-335. doi: 10.1016/j.mayocp.2018.12.012. Mayo Clin Proc. 2019. PMID: 30711128 Review.
FIGO System 2, published in 2011, focused on classifications of AUB etiology into structural and nonstructural entities using the PALM-COEIN (polyp[s], adenomyosis, leiomyoma, malignancy, coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic, and not yet c …
FIGO System 2, published in 2011, focused on classifications of AUB etiology into structural and nonstructural entities using the PALM-COEIN …
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA. Al-Hendy A, et al. N Engl J Med. 2021 Feb 18;384(7):630-642. doi: 10.1056/NEJMoa2008283. N Engl J Med. 2021. PMID: 33596357 Free PMC article. Clinical Trial.
Epidemiology of uterine fibroids: a systematic review.
Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Stewart EA, et al. BJOG. 2017 Sep;124(10):1501-1512. doi: 10.1111/1471-0528.14640. Epub 2017 May 13. BJOG. 2017. PMID: 28296146
Black race and 11 other factors affect uterine fibroid risk....
Black race and 11 other factors affect uterine fibroid risk....
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
Al-Hendy A, Lukes AS, Poindexter AN 3rd, Venturella R, Villarroel C, McKain L, Li Y, Wagman RB, Stewart EA. Al-Hendy A, et al. Obstet Gynecol. 2022 Dec 1;140(6):920-930. doi: 10.1097/AOG.0000000000004988. Epub 2022 Nov 2. Obstet Gynecol. 2022. PMID: 36357960 Free PMC article. Clinical Trial.
At week 52, 59.0% of patients with anemia at baseline had improvements in hemoglobin concentration of greater than 2 g/dL. Distress due to uterine leiomyoma-associated symptoms measured by the BPD (Bleeding and Pelvic Discomfort) scale score was reduced by 51.3 points. Sus …
At week 52, 59.0% of patients with anemia at baseline had improvements in hemoglobin concentration of greater than 2 g/dL. Distress due to u …
Nononcologic Embolization.
De la Garza-Ramos C, Salei A, Caridi TM. De la Garza-Ramos C, et al. Semin Intervent Radiol. 2022 Nov 17;39(4):416-420. doi: 10.1055/s-0042-1758077. eCollection 2022 Aug. Semin Intervent Radiol. 2022. PMID: 36406022 Free PMC article. Review.
This article reviews available evidence comparing various particles used for uterine fibroid embolization and prostate artery embolization. In addition, we provide an overview of periprocedural pharmacology and protocols facilitating same-day discharge for these int …
This article reviews available evidence comparing various particles used for uterine fibroid embolization and prostate artery …
Hysteroscopic Myomectomy.
Moawad NS, Palin H. Moawad NS, et al. Obstet Gynecol Clin North Am. 2022 Jun;49(2):329-353. doi: 10.1016/j.ogc.2022.02.012. Obstet Gynecol Clin North Am. 2022. PMID: 35636812 Review.
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Donnez J, et al. Lancet. 2022 Sep 17;400(10356):896-907. doi: 10.1016/S0140-6736(22)01475-1. Lancet. 2022. PMID: 36116480 Clinical Trial.
Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses gonadal steroids and might reduce uterine-fibroid-associated signs. Two phase 3 trials were conducted to confirm the efficacy and safety of l …
Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses gonadal steroid …
Radiofrequency Ablation for the Treatment of Uterine Fibroids: A Systematic Review and Meta-Analysis by the AAGL Practice Committee.
Chen I, Berman JM, Balk EM, Saldanha IJ, Kowalczewski E, Yi J, Zanotti S, Al Hilli M, Kho KA. Chen I, et al. J Minim Invasive Gynecol. 2025 Jan;32(1):74-91. doi: 10.1016/j.jmig.2024.09.011. Epub 2024 Sep 12. J Minim Invasive Gynecol. 2025. PMID: 39277104 Free article.
Meta-analyses of health-related quality of life scores demonstrated significant improvements in scores from baseline for Uterine Fibroid Symptoms and Quality of Life (53.4, 95% CI 48.2, 58.5; 19 studies), EuroQol-5 dimension (71.6, 95% CI 65.0, 78.1; 4 studies), and …
Meta-analyses of health-related quality of life scores demonstrated significant improvements in scores from baseline for Uterine F
254 results